Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:34:09 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:NUWE from 2023-04-30 to 2024-04-29 - 28 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-26 09:18U:NUWENews ReleaseNuwellis Announces Pricing of $2.7 Million Public Offering
2024-04-09 09:00U:NUWENews ReleaseNuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow(TM) System at Henry Ford Health
2024-03-07 09:09U:NUWENews ReleaseLate-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
2024-03-05 08:00U:NUWENews ReleaseNuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 09:00U:NUWENews ReleaseNuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
2024-02-22 07:58U:NUWENews ReleaseNuwellis ¢ € ™ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune ¢ „ ¢
2024-02-20 17:07U:NUWENews ReleaseNuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-20 08:43U:NUWENews ReleaseNuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
2024-02-06 09:00U:NUWENews ReleaseNew Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
2024-01-04 15:05U:NUWENews ReleaseNuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
2023-11-28 08:00U:NUWENews ReleaseNew Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
2023-11-14 16:30U:NUWENews ReleaseNuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-07 08:00U:NUWENews ReleaseNuwellis, Inc. Announces Third Quarter 2023 Financial Results
2023-11-01 08:00U:NUWENews ReleaseNuwellis Announces Board of Directors Transition
2023-10-31 08:00U:NUWENews ReleaseNuwellis ¢ € ™ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
2023-10-18 16:15U:NUWENews ReleaseNuwellis, Inc. To Announce Third Quarter 2023 Financial Results ‚  on November 7, 2023
2023-10-17 16:15U:NUWENews ReleaseNuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
2023-10-13 08:30U:NUWENews ReleaseNuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
2023-10-10 08:00U:NUWENews ReleaseNuwellis Provides Regulatory Update on SeaStar Medical ¢ € ™s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
2023-09-11 16:15U:NUWENews ReleaseNuwellis to Present at the Gilmartin Group Emerging Growth Showcase
2023-08-08 08:15U:NUWENews ReleaseNuwellis, Inc. Announces Second Quarter 2023 Financial Results
2023-08-08 08:00U:NUWENews ReleaseNuwellis Announces Plan for CFO Transition
2023-07-18 16:15U:NUWENews ReleaseNuwellis, Inc. To Announce Second Quarter 2023 Financial Results ‚  on August 8, 2023
2023-06-20 08:30U:NUWENews ReleaseNuwellis Inc. Announces Pilot Agreement With DaVita Inc.
2023-06-13 16:15U:NUWENews ReleaseNuwellis to Participate in the Maxim Group Virtual Healthcare Conference
2023-06-05 16:15U:NUWENews ReleaseNuwellis Announces the Appointment of Mike McCormick to its Board of Directors
2023-05-22 17:10U:NUWENews ReleaseNuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-09 08:00U:NUWENews ReleaseNuwellis, Inc. Announces First Quarter 2023 Financial Results